Biorestorative Therapies Inc (BRTX) financial statements (2021 and earlier)

Company profile

Business Address 40 MARCUS DRIVE
MELVILLE, NY 11747
State of Incorp. DE
Fiscal Year End December 31
SIC 809 - Miscellaneous Health And Allied Services, Not (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments0001000
Cash and cash equivalents0001000
Receivables0000000
Prepaid expense00     
Other undisclosed current assets  00000
Total current assets:0001100
Noncurrent Assets
Operating lease, right-of-use asset11   
Property, plant and equipment0000000
Intangible assets, net (including goodwill)1111111
Intangible assets, net (excluding goodwill)1111111
Deferred costs  00   
Other undisclosed noncurrent assets  0  00
Total noncurrent assets:1111111
TOTAL ASSETS:1112211
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6644424
Accounts payable2222222
Accrued liabilities33332 2
Employee-related liabilities  0    
Interest and dividends payable11     
Debt8785443
Derivative instruments and hedges, liabilities4111111
Other undisclosed current liabilities0011030
Total current liabilities:18141411999
Noncurrent Liabilities
Long-term debt and lease obligation0100011
Long-term debt, excluding current maturities  00011
Operating lease, liability01   
Liabilities, other than long-term debt  00000
Accounts payable and accrued liabilities  00000
Other undisclosed noncurrent liabilities(0)(1)   0 
Total noncurrent liabilities:0 00111
Total liabilities:1914141191010
Stockholders' equity
Stockholders' equity attributable to parent(18)(13)(12)(9)(8)(9)(9)
Common stock0000000
Additional paid in capital68666563605551
Accumulated deficit(86)(79)(77)(72)(68)(64)(60)
Total stockholders' equity:(18)(13)(12)(9)(8)(9)(9)
TOTAL LIABILITIES AND EQUITY:1112211

Income statement (P&L) ($ in millions)

3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
Gross profit:0000000
Operating expenses(1)(2)(2)(2)(2)(2)(1)
Operating loss:(1)(2)(2)(2)(2)(2)(1)
Nonoperating income (expense)(7)1(3)(2)(2)(1)(2)
Interest and debt expense(1)0(1)(1)(0)(1)(0)
Net loss:(8)(1)(6)(5)(4)(5)(3)
Other undisclosed net income (loss) attributable to parent1(0)11010
Net loss available to common stockholders, diluted:(8)(2)(5)(4)(4)(4)(3)

Comprehensive Income ($ in millions)

3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
Net loss:(8)(1)(6)(5)(4)(5)(3)
Comprehensive loss, net of tax, attributable to parent:(8)(1)(6)(5)(4)(5)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: